Home Cart Sign in  
Chemical Structure| 89-25-8 Chemical Structure| 89-25-8

Structure of Edaravone
CAS No.: 89-25-8

Chemical Structure| 89-25-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Edaravone is a novel, potent free radical scavenger that inhibits MMP-9-related brain hemorrhage in rats treated with tissue plasminogen activator.

Synonyms: MCI-186; NSC 2629; Arone

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Edaravone

CAS No. :89-25-8
Formula : C10H10N2O
M.W : 174.20
SMILES Code : O=C1CC(C)=NN1C2=CC=CC=C2
Synonyms :
MCI-186; NSC 2629; Arone
MDL No. :MFCD00003138
InChI Key :QELUYTUMUWHWMC-UHFFFAOYSA-N
Pubchem ID :4021

Safety of Edaravone

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01518231 Stroke Phase 1 Unknown December 2013 China, Zhejiang ... More >> Yaguo Li Recruiting Hangzhou, Zhejiang, China, 310013 Contact: Yumiao Zhou, master    0086-0571-87987373 ext 5094    zlf859@yahoo.com.cn Less <<
NCT01556854 - Unknown June 2014 China, Beijing ... More >> Tiantan hospital Recruiting Beijing, Beijing, China, 100050 Contact: Yilong Wang, Doctor    00861067098222    yilong528@Gmail.com Less <<
NCT01894334 Acute Aortic Dissection Not Applicable Unknown January 2015 -
NCT03346538 Acute Ischemic Stroke Phase 2 Terminated(Business objectives... More >> have changed.) Less << - Japan ... More >> Investigational site 13 Aichi, Japan Investigational site 39 Aomori, Japan Investigational site 19 Chiba, Japan Investigational site 28 Chiba, Japan Investigational site 33 Ehime, Japan Investigational site 10 Fukui, Japan Investigational site 05 Fukuoka, Japan Investigational site 09 Fukuoka, Japan Investigational site 11 Fukuoka, Japan Investigational site 12 Fukuoka, Japan Investigational site 18 Fukuoka, Japan Investigational site 21 Fukuoka, Japan Investigational site 32 Fukuoka, Japan Investigational site 37 Fukuoka, Japan Investigational site 07 Fukushima, Japan Investigational site 08 Fukushima, Japan Investigational site 15 Gifu, Japan Investigational site 23 Gifu, Japan Investigational site 02 Gunma, Japan Investigational site 01 Hokkaido, Japan Investigational site 22 Hokkaido, Japan Investigational site 06 Hyogo, Japan Investigational site 30 Hyogo, Japan Investigational site 42 Hyogo, Japan Investigational site 43 Ishikawa, Japan Investigational site 27 Iwate, Japan Investigational site 40 Kanagawa, Japan Investigational site 24 Kochi, Japan Investigational site 35 Miyagi, Japan Investigational site 16 Nagano, Japan Investigational site 20 Nagano, Japan Investigational site 44 Okayama, Japan Investigational site 41 Okinawa, Japan Investigational site 03 Osaka, Japan Investigational site 25 Osaka, Japan Investigational site 38 Saga, Japan Investigational site 31 Saitama, Japan Investigational site 14 Shimane, Japan Investigational site 29 Tochigi, Japan Investigational site 36 Tochigi, Japan Investigational site 17 Tokyo, Japan Investigational site 45 Tokyo, Japan Investigational site 34 Yamagata, Japan Investigational site 04 Yamaguchi, Japan Investigational site 26 Yamaguchi, Japan Less <<
NCT01492686 Amyotrophic Lateral Sclerosis ... More >>(ALS) Less << Phase 3 Completed - Japan ... More >> Osaka, Japan Less <<
NCT00153946 Stroke PHASE4 COMPLETED 2025-05-08 EAST Study Office c/o National... More >> Cardiovascular Center, Suita, Osaka, 565-8565, Japan Less <<
NCT00330681 Amyotrophic Lateral Sclerosis ... More >>(ALS) Less << Phase 3 Completed - -
NCT00415519 - Completed - -
NCT01929096 Acute Ischemic Stroke Phase 2 Completed - -
NCT00424463 Amyotrophic Lateral Sclerosis ... More >>(ALS) Less << Phase 3 Completed - Japan ... More >> National Hospital Organization Miyagi National Hospital Watari-gun, Miyagi-ken, Japan Less <<
NCT00265239 Myocardial Infarction ... More >> Reperfusion Injury Less << Phase 4 Completed - Japan ... More >> Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University Kumamoto, Japan, 860-8556 Less <<
NCT00424463 - Completed - -
NCT00821821 Acute Ischemic Stroke (AIS) Phase 2 Completed - Finland ... More >> Helsinki University Central Hospital Helsinki, Finland Netherlands Erasmus Medical Center Rotterdam, Netherlands United Kingdom Newcastle upon Tyne Hospitals NHS Foundation Trust Newcastle, United Kingdom Less <<
NCT00200356 Cerebral Infarction Phase 4 Completed - -
NCT00330681 - Completed - -
NCT00200356 - Completed - -
NCT00415519 Amyotrophic Lateral Sclerosis ... More >>(ALS) Less << Phase 3 Completed - -
NCT00265239 - Completed - -
NCT03289208 Renal Impairment|Healthy PHASE1 COMPLETED 2018-04-20 Investigational site, Tokyo, J... More >>apan Less <<
NCT03289234 Hepatic Impairment|Healthy PHASE1 COMPLETED 2018-07-24 Investigational site, Fukuoka,... More >> Japan|Investigational site, Tokyo, Japan Less <<
NCT00821821 - Completed - -
NCT03272802 Neuromuscular Diseases Phase 1 Phase 2 Recruiting March 16, 2019 Iran, Islamic Republic of ... More >> EMG Department, Alzahra Hospital Recruiting Isfahan, Iran, Islamic Republic of Less <<
NCT01865201 Nasopharyngeal Carcinoma ... More >> Brain Necrosis Less << Phase 2 Completed - China, Guangdong ... More >> Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University Guangzhou, Guangdong, China, 510120 Less <<
NCT02644915 Kidney Transplantation Not Applicable Unknown October 2016 -
NCT03664544 Severe Hepatic Impairment|Heal... More >>thy Less << PHASE1 COMPLETED 2019-03-25 Investigational Centre, Prague... More >>, Czechia|Investigational Centre, Miskolc, Hungary|Investigational Centre, Bratislava, Slovakia Less <<
NCT02430350 Acute Ischemic Stroke Phase 3 Completed - -
NCT05540262 Optic Neuritis RECRUITING 2024-12-31 Yi Du, Nanning, 530021, China

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

5.74mL

1.15mL

0.57mL

28.70mL

5.74mL

2.87mL

57.41mL

11.48mL

5.74mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories